U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Refractory Urethral Urothelial Carcinoma

MedGen UID:
1780766
•Concept ID:
C5447547
•
Neoplastic Process

Definition

Urethral urothelial carcinoma that is resistant to treatment. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVRefractory Urethral Urothelial Carcinoma

Recent clinical studies

Etiology

Secondary Urethral Malignancies Following Prostate Brachytherapy.
Agrawal S, Lacy JM, Bagga H, Angermeier KW, Ciezki J, Tendulkar RD, Reddy CA, Wood HM
Urology 2017 Dec;110:172-176. Epub 2017 Sep 4 doi: 10.1016/j.urology.2017.08.036. PMID: 28882777
Oral 5-aminolevulinic acid in simultaneous photodynamic diagnosis of upper and lower urinary tract transitional cell carcinoma - a prospective audit.
Ahmad S, Aboumarzouk O, Somani B, Nabi G, Kata SG
BJU Int 2012 Dec;110(11 Pt B):E596-600. Epub 2012 Jul 3 doi: 10.1111/j.1464-410X.2012.11326.x. PMID: 22758907
Risk of continued intravesical therapy and delayed cystectomy in BCG-refractory superficial bladder cancer: an investigational approach.
Luciani LG, Neulander E, Murphy WM, Wajsman Z
Urology 2001 Sep;58(3):376-9. doi: 10.1016/s0090-4295(01)01187-6. PMID: 11549484
Intravesical bacillus Calmette-Guerin therapy for in situ transitional cell carcinoma involving the prostatic urethra.
Bretton PR, Herr HW, Whitmore WF Jr, Badalament RA, Kimmel M, Provet J, Oettgen HF, Melamed MR, Fair WR
J Urol 1989 Apr;141(4):853-6. doi: 10.1016/s0022-5347(17)41031-7. PMID: 2926879

Diagnosis

Secondary Urethral Malignancies Following Prostate Brachytherapy.
Agrawal S, Lacy JM, Bagga H, Angermeier KW, Ciezki J, Tendulkar RD, Reddy CA, Wood HM
Urology 2017 Dec;110:172-176. Epub 2017 Sep 4 doi: 10.1016/j.urology.2017.08.036. PMID: 28882777
Primary mucin-producing urothelial-type adenocarcinoma of the prostatic urethra diagnosed on TURP: a case report and review of literature.
Sebesta EM, Mirheydar HS, Parsons JK, Wang-Rodriguez J, Kader AK
BMC Urol 2014 May 22;14:39. doi: 10.1186/1471-2490-14-39. PMID: 24885582Free PMC Article
Oral 5-aminolevulinic acid in simultaneous photodynamic diagnosis of upper and lower urinary tract transitional cell carcinoma - a prospective audit.
Ahmad S, Aboumarzouk O, Somani B, Nabi G, Kata SG
BJU Int 2012 Dec;110(11 Pt B):E596-600. Epub 2012 Jul 3 doi: 10.1111/j.1464-410X.2012.11326.x. PMID: 22758907
Carcinoma in situ of the urinary bladder: review of clinicopathologic characteristics with an emphasis on aspects related to molecular diagnostic techniques and prognosis.
Nese N, Gupta R, Bui MH, Amin MB
J Natl Compr Canc Netw 2009 Jan;7(1):48-57. doi: 10.6004/jnccn.2009.0004. PMID: 19176205

Therapy

Oral 5-aminolevulinic acid in simultaneous photodynamic diagnosis of upper and lower urinary tract transitional cell carcinoma - a prospective audit.
Ahmad S, Aboumarzouk O, Somani B, Nabi G, Kata SG
BJU Int 2012 Dec;110(11 Pt B):E596-600. Epub 2012 Jul 3 doi: 10.1111/j.1464-410X.2012.11326.x. PMID: 22758907
Positive response to bevacizumab in a patient with metastatic, chemotherapy-refractory urothelial carcinoma.
Osai WE, Ng CS, Pagliaro LC
Anticancer Drugs 2008 Apr;19(4):427-9. doi: 10.1097/CAD.0b013e3282f52bef. PMID: 18454053
Risk of continued intravesical therapy and delayed cystectomy in BCG-refractory superficial bladder cancer: an investigational approach.
Luciani LG, Neulander E, Murphy WM, Wajsman Z
Urology 2001 Sep;58(3):376-9. doi: 10.1016/s0090-4295(01)01187-6. PMID: 11549484
Intravesical bacillus Calmette-Guerin therapy for in situ transitional cell carcinoma involving the prostatic urethra.
Bretton PR, Herr HW, Whitmore WF Jr, Badalament RA, Kimmel M, Provet J, Oettgen HF, Melamed MR, Fair WR
J Urol 1989 Apr;141(4):853-6. doi: 10.1016/s0022-5347(17)41031-7. PMID: 2926879

Prognosis

Secondary Urethral Malignancies Following Prostate Brachytherapy.
Agrawal S, Lacy JM, Bagga H, Angermeier KW, Ciezki J, Tendulkar RD, Reddy CA, Wood HM
Urology 2017 Dec;110:172-176. Epub 2017 Sep 4 doi: 10.1016/j.urology.2017.08.036. PMID: 28882777
Carcinoma in situ of the urinary bladder: review of clinicopathologic characteristics with an emphasis on aspects related to molecular diagnostic techniques and prognosis.
Nese N, Gupta R, Bui MH, Amin MB
J Natl Compr Canc Netw 2009 Jan;7(1):48-57. doi: 10.6004/jnccn.2009.0004. PMID: 19176205
Risk of continued intravesical therapy and delayed cystectomy in BCG-refractory superficial bladder cancer: an investigational approach.
Luciani LG, Neulander E, Murphy WM, Wajsman Z
Urology 2001 Sep;58(3):376-9. doi: 10.1016/s0090-4295(01)01187-6. PMID: 11549484
Intravesical bacillus Calmette-Guerin therapy for in situ transitional cell carcinoma involving the prostatic urethra.
Bretton PR, Herr HW, Whitmore WF Jr, Badalament RA, Kimmel M, Provet J, Oettgen HF, Melamed MR, Fair WR
J Urol 1989 Apr;141(4):853-6. doi: 10.1016/s0022-5347(17)41031-7. PMID: 2926879

Clinical prediction guides

New concept in urologic surgery: The total extended genital sparing radical cystectomy in women.
Cisternino A, Capone L, Rosati A, Latiano C, Sebastio N, Colella A, Cretì G
Arch Ital Urol Androl 2023 May 22;95(2):11058. doi: 10.4081/aiua.2023.11058. PMID: 37212881

Supplemental Content

Table of contents

    Practice guidelines

    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...